Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Animal models of respiratory syncytial virus infection.

Taylor G.

Vaccine. 2017 Jan 11;35(3):469-480. doi: 10.1016/j.vaccine.2016.11.054. Epub 2016 Nov 29. Review.

2.

Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE Jr.

Vaccine. 2016 Feb 10;34(7):950-6. doi: 10.1016/j.vaccine.2015.12.045. Epub 2016 Jan 7.

3.

Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children.

Kim YI, Murphy R, Majumdar S, Harrison LG, Aitken J, DeVincenzo JP.

Pediatr Res. 2015 Oct;78(4):380-8. doi: 10.1038/pr.2015.122. Epub 2015 Jun 24.

4.

Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.

Lee YN, Hwang HS, Kim MC, Lee YT, Lee JS, Moore ML, Kang SM.

Antiviral Res. 2015 Mar;115:1-8. doi: 10.1016/j.antiviral.2014.12.009. Epub 2014 Dec 13.

5.

Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

Kumari S, Crim RL, Kulkarni A, Audet SA, Mdluli T, Murata H, Beeler JA.

Clin Vaccine Immunol. 2014 Mar;21(3):383-90. doi: 10.1128/CVI.00594-13. Epub 2014 Jan 8.

6.

A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV.

Turner TM, Jones LP, Tompkins SM, Tripp RA.

J Virol. 2013 Oct;87(19):10792-804. doi: 10.1128/JVI.01724-13. Epub 2013 Jul 31.

8.

Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.

Luongo C, Winter CC, Collins PL, Buchholz UJ.

J Virol. 2012 Oct;86(19):10792-804. doi: 10.1128/JVI.01227-12. Epub 2012 Jul 25.

9.

Respiratory syncytial virus vaccine development.

Murata Y.

Clin Lab Med. 2009 Dec;29(4):725-39. doi: 10.1016/j.cll.2009.07.004. Review.

10.

Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway.

Flotte TR, Fischer AC, Goetzmann J, Mueller C, Cebotaru L, Yan Z, Wang L, Wilson JM, Guggino WB, Engelhardt JF.

Mol Ther. 2010 Mar;18(3):594-600. doi: 10.1038/mt.2009.230. Epub 2009 Oct 13.

11.

Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.

Luongo C, Yang L, Winter CC, Spann KM, Murphy BR, Collins PL, Buchholz UJ.

Vaccine. 2009 Sep 18;27(41):5667-76. doi: 10.1016/j.vaccine.2009.07.022. Epub 2009 Jul 29.

12.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22. Epub 2007 Oct 10.

13.

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.

Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA.

J Virol. 2004 Oct;78(20):11198-207.

14.

The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, McAuliffe JM, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2004 Jul;78(13):6927-37.

15.

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS.

J Virol. 2004 Jun;78(11):6043-7.

16.

More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Bukreyev A, Skiadopoulos MH, McAuliffe J, Murphy BR, Collins PL, Schmidt AC.

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16987-91. Epub 2002 Dec 13.

19.
20.

Supplemental Content

Support Center